Comparison · NCT03163446-5f6aa313
MRSA - CF-301 vs MRSA - Placebo: All-cause Mortality at Day 30 in MRSA Subgroup
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MRSA - CF-301 vs MRSA - Placebo: All-cause Mortality at Day 30 in MRSA Subgroup. Trial comparisons, record NCT03163446-5f6aa313. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03163446-5f6aa313
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.037 | 0.00657 | 0.183 | wilson | |
| Risk in group 2 | 0.25 | 0.102 | 0.495 | wilson | |
| Risk difference, group 1 minus group 2 | -0.213 | -0.46 | -0.00508 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.148 | 0.0181 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.115 | 0.0116 | 1.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on MRSA - CF-301 than on MRSA - Placebo | 4.7 | 2.17 | 197 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MRSA - CF-301 | Patients in the MRSA Subgroup that received CF-301 | 1 | 27 | OG000 |
| Group 2 | MRSA - Placebo | Patients in the MRSA Subgroup that received Placebo | 4 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- POST_HOC
- Title
- All-cause Mortality at Day 30 in MRSA Subgroup
- Description
- 30-day all-cause mortality in the MRSA subgroup in the mITT
- Time frame
- Day 30
- Population
- Microbiological Intent-to-Treat (mITT) population
Source ClinicalTrials.gov
Trial
- Title
- Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
- NCT number
- NCT03163446
- Phases
- PHASE2
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- CF-301, Placebo
- Lead sponsor
- ContraFect
- Results first posted
- 2021-10-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03163446?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03163446-5f6aa313